# A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients

> **NCT00996918** · PHASE3 · TERMINATED · sponsor: **Pfizer** · enrollment: 198 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** Bapineuzumab 0.5 mg/kg
- **DRUG:** Bapineuzumab 1.0 m/kg

## Key facts

- **NCT ID:** NCT00996918
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2012-11
- **Final completion:** 2012-11
- **Target enrollment:** 198 (ACTUAL)
- **Why stopped:** The study was terminated on August 6, 2012, because 2 large Phase 3 studies showed no clinical benefit. This decision was not based on any new safety concerns.
- **Last updated:** 2014-01-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00996918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00996918, "A Long-Term Safety And Tolerability Study Of Bapineuzumab In Alzheimer Disease Patients". Retrieved via AI Analytics 2026-08-03 from https://api.ai-analytics.org/clinical/NCT00996918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*